A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

To join this study, you generally need to be between 18 and 75 years old and have been diagnosed with type 2 diabetes. You also need to be overweight or obese (this is measured by something called your Body Mass Index, or BMI). Your blood sugar control, measured by a test called HbA1c, needs to be within a specific range.

It's important that you've tried to lose weight through diet and exercise before, but haven't been successful. You might be managing your diabetes with diet and exercise alone, or taking metformin or a specific type of medication called an SGLT-2 inhibitor.

There are also some reasons why you might not be able to join. For instance, if you have type 1 diabetes, or have had severe low blood sugar episodes recently. Certain eye problems related to diabetes, specific nerve issues, or taking particular medications for weight loss or diabetes could also mean you're not suitable for this study.

If you decide to take part in this study, you'll be assigned by chance to either receive the new medicine, Enicepatide, at a low, medium, or high dose, or a placebo (which looks like the medicine but contains no active ingredients). Neither you nor your study doctor will know which one you are getting. You'll have regular visits to the study clinic where the research team will check your health, take blood and urine samples, and monitor your blood sugar levels and weight. They will also ask you questions about how you feel and if you're experiencing any side effects. You'll receive the study medication and instructions on how to use it. The total duration of your participation in the study will involve regular follow-up visits over a period that will be explained to you in detail.